{
    "markdown": "<a id='434cfaab-5744-4845-9983-7a19c8ee0bb3'></a>\n\n*Achieving Clarity, Renewing Confidence*\n\n<a id='ce90ecd3-4802-49c6-9f8b-1e74f766be55'></a>\n\nINTRODUCTION\nThe PREMARIN\u00ae Family of Products offers significant relief from menopausal symptoms, prevents rapid bone loss in the early postmenopausal years, and has been the standard of care for managing the constellation of symptoms associated with postmenopausal estrogen loss for more than 60 years. However, a recent report from the Women's Health Initiative has resulted in confusion among health care providers and patients about the balance of risks and benefits associated with the use of postmenopausal hormone therapy (HT). Now, more than ever, physicians and other health care professionals need appropriate information on the benefits and risks of the PREMARIN Family of Products to ensure that the standard of care for postmenopausal health is adequately promoted and that patients receive accurate information and individualized counseling about their personal risk-benefit profile.\n\n<a id='7fded707-d30f-4ab6-9a7b-66158dfeb917'></a>\n\nIn July 1997, DesignWrite initiated a comprehensive, peer-reviewed publication program in support of the PREMARIN Family of Products. The specific objectives of this program were:\n1) to increase physician awareness of the multitude of benefits that HT provides for postmenopausal women; 2) to diminish the negative perceptions associated with estrogens; and 3) to blunt the competitive threat of new products introduced as alternatives to postmenopausal HT.\n\n<a id='66a70ddf-280b-4fb6-9fab-611781e905f1'></a>\n\nThe success of this initial endeavor has lead to the development and implementation of a number of programs, including:\n\n* Over 40 peer-reviewed publications\n* More than 40 scientific abstracts and posters at national meetings\n* Council on Hormone Education\n* Sales training backgrounders and journal article responses\n* Advisory boards/expert forums (with executive summaries) on selective estrogen-receptor modulators, lower-dose postmenopausal HT, acute cognitive symptoms, breast health, and sexuality\n* Journal supplements\n* Internal white papers\n* Pharmaceutical compendia surveillance program\n* Publications management program\n* Editorial assistance for key advocates\n* Women's HOPE Study clinical trial publications and associated slide kits\n* Branded slide kit for the Visiting Speakers Bureau\n* Progestins slide kit disseminated by Global Medical Affairs\n\n<a id='564a2df3-3a6f-47b8-aae4-a2e8d5335e25'></a>\n\nSource: https://www.industrydocuments.ucsf.edu/docs/fyvw0217\n\n<a id='c96f98b0-87d6-4365-9f55-462f5d77ab54'></a>\n\nDWRITE 066196",
    "chunks": [
        {
            "markdown": "<a id='434cfaab-5744-4845-9983-7a19c8ee0bb3'></a>\n\n*Achieving Clarity, Renewing Confidence*",
            "type": "text",
            "id": "434cfaab-5744-4845-9983-7a19c8ee0bb3",
            "grounding": {
                "box": {
                    "left": 0.5405682325363159,
                    "top": 0.07127787172794342,
                    "right": 0.8696494102478027,
                    "bottom": 0.09548883140087128
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='ce90ecd3-4802-49c6-9f8b-1e74f766be55'></a>\n\nINTRODUCTION\nThe PREMARIN\u00ae Family of Products offers significant relief from menopausal symptoms, prevents rapid bone loss in the early postmenopausal years, and has been the standard of care for managing the constellation of symptoms associated with postmenopausal estrogen loss for more than 60 years. However, a recent report from the Women's Health Initiative has resulted in confusion among health care providers and patients about the balance of risks and benefits associated with the use of postmenopausal hormone therapy (HT). Now, more than ever, physicians and other health care professionals need appropriate information on the benefits and risks of the PREMARIN Family of Products to ensure that the standard of care for postmenopausal health is adequately promoted and that patients receive accurate information and individualized counseling about their personal risk-benefit profile.",
            "type": "text",
            "id": "ce90ecd3-4802-49c6-9f8b-1e74f766be55",
            "grounding": {
                "box": {
                    "left": 0.10964789986610413,
                    "top": 0.12037411332130432,
                    "right": 0.8674274682998657,
                    "bottom": 0.33126702904701233
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='7fded707-d30f-4ab6-9a7b-66158dfeb917'></a>\n\nIn July 1997, DesignWrite initiated a comprehensive, peer-reviewed publication program in support of the PREMARIN Family of Products. The specific objectives of this program were:\n1) to increase physician awareness of the multitude of benefits that HT provides for postmenopausal women; 2) to diminish the negative perceptions associated with estrogens; and 3) to blunt the competitive threat of new products introduced as alternatives to postmenopausal HT.",
            "type": "text",
            "id": "7fded707-d30f-4ab6-9a7b-66158dfeb917",
            "grounding": {
                "box": {
                    "left": 0.11109200119972229,
                    "top": 0.33874163031578064,
                    "right": 0.8536977767944336,
                    "bottom": 0.44424495100975037
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='66a70ddf-280b-4fb6-9fab-611781e905f1'></a>\n\nThe success of this initial endeavor has lead to the development and implementation of a number of programs, including:\n\n* Over 40 peer-reviewed publications\n* More than 40 scientific abstracts and posters at national meetings\n* Council on Hormone Education\n* Sales training backgrounders and journal article responses\n* Advisory boards/expert forums (with executive summaries) on selective estrogen-receptor modulators, lower-dose postmenopausal HT, acute cognitive symptoms, breast health, and sexuality\n* Journal supplements\n* Internal white papers\n* Pharmaceutical compendia surveillance program\n* Publications management program\n* Editorial assistance for key advocates\n* Women's HOPE Study clinical trial publications and associated slide kits\n* Branded slide kit for the Visiting Speakers Bureau\n* Progestins slide kit disseminated by Global Medical Affairs",
            "type": "text",
            "id": "66a70ddf-280b-4fb6-9fab-611781e905f1",
            "grounding": {
                "box": {
                    "left": 0.1089007556438446,
                    "top": 0.4528042674064636,
                    "right": 0.8628273010253906,
                    "bottom": 0.9112815260887146
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='564a2df3-3a6f-47b8-aae4-a2e8d5335e25'></a>\n\nSource: https://www.industrydocuments.ucsf.edu/docs/fyvw0217",
            "type": "marginalia",
            "id": "564a2df3-3a6f-47b8-aae4-a2e8d5335e25",
            "grounding": {
                "box": {
                    "left": 0.2166537046432495,
                    "top": 0.9774618148803711,
                    "right": 0.785216212272644,
                    "bottom": 0.9998968839645386
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='c96f98b0-87d6-4365-9f55-462f5d77ab54'></a>\n\nDWRITE 066196",
            "type": "marginalia",
            "id": "c96f98b0-87d6-4365-9f55-462f5d77ab54",
            "grounding": {
                "box": {
                    "left": 0.8406700491905212,
                    "top": 0.9730968475341797,
                    "right": 0.9733803868293762,
                    "bottom": 0.9925980567932129
                },
                "page": 0
            }
        }
    ],
    "splits": [
        {
            "class": "full",
            "identifier": "full",
            "pages": [
                0
            ],
            "markdown": "<a id='434cfaab-5744-4845-9983-7a19c8ee0bb3'></a>\n\n*Achieving Clarity, Renewing Confidence*\n\n<a id='ce90ecd3-4802-49c6-9f8b-1e74f766be55'></a>\n\nINTRODUCTION\nThe PREMARIN\u00ae Family of Products offers significant relief from menopausal symptoms, prevents rapid bone loss in the early postmenopausal years, and has been the standard of care for managing the constellation of symptoms associated with postmenopausal estrogen loss for more than 60 years. However, a recent report from the Women's Health Initiative has resulted in confusion among health care providers and patients about the balance of risks and benefits associated with the use of postmenopausal hormone therapy (HT). Now, more than ever, physicians and other health care professionals need appropriate information on the benefits and risks of the PREMARIN Family of Products to ensure that the standard of care for postmenopausal health is adequately promoted and that patients receive accurate information and individualized counseling about their personal risk-benefit profile.\n\n<a id='7fded707-d30f-4ab6-9a7b-66158dfeb917'></a>\n\nIn July 1997, DesignWrite initiated a comprehensive, peer-reviewed publication program in support of the PREMARIN Family of Products. The specific objectives of this program were:\n1) to increase physician awareness of the multitude of benefits that HT provides for postmenopausal women; 2) to diminish the negative perceptions associated with estrogens; and 3) to blunt the competitive threat of new products introduced as alternatives to postmenopausal HT.\n\n<a id='66a70ddf-280b-4fb6-9fab-611781e905f1'></a>\n\nThe success of this initial endeavor has lead to the development and implementation of a number of programs, including:\n\n* Over 40 peer-reviewed publications\n* More than 40 scientific abstracts and posters at national meetings\n* Council on Hormone Education\n* Sales training backgrounders and journal article responses\n* Advisory boards/expert forums (with executive summaries) on selective estrogen-receptor modulators, lower-dose postmenopausal HT, acute cognitive symptoms, breast health, and sexuality\n* Journal supplements\n* Internal white papers\n* Pharmaceutical compendia surveillance program\n* Publications management program\n* Editorial assistance for key advocates\n* Women's HOPE Study clinical trial publications and associated slide kits\n* Branded slide kit for the Visiting Speakers Bureau\n* Progestins slide kit disseminated by Global Medical Affairs\n\n<a id='564a2df3-3a6f-47b8-aae4-a2e8d5335e25'></a>\n\nSource: https://www.industrydocuments.ucsf.edu/docs/fyvw0217\n\n<a id='c96f98b0-87d6-4365-9f55-462f5d77ab54'></a>\n\nDWRITE 066196",
            "chunks": [
                "434cfaab-5744-4845-9983-7a19c8ee0bb3",
                "ce90ecd3-4802-49c6-9f8b-1e74f766be55",
                "7fded707-d30f-4ab6-9a7b-66158dfeb917",
                "66a70ddf-280b-4fb6-9fab-611781e905f1",
                "564a2df3-3a6f-47b8-aae4-a2e8d5335e25",
                "c96f98b0-87d6-4365-9f55-462f5d77ab54"
            ]
        }
    ],
    "grounding": {
        "434cfaab-5744-4845-9983-7a19c8ee0bb3": {
            "box": {
                "left": 0.5405682325363159,
                "top": 0.07127787172794342,
                "right": 0.8696494102478027,
                "bottom": 0.09548883140087128
            },
            "page": 0,
            "type": "chunkText"
        },
        "ce90ecd3-4802-49c6-9f8b-1e74f766be55": {
            "box": {
                "left": 0.10964789986610413,
                "top": 0.12037411332130432,
                "right": 0.8674274682998657,
                "bottom": 0.33126702904701233
            },
            "page": 0,
            "type": "chunkText"
        },
        "7fded707-d30f-4ab6-9a7b-66158dfeb917": {
            "box": {
                "left": 0.11109200119972229,
                "top": 0.33874163031578064,
                "right": 0.8536977767944336,
                "bottom": 0.44424495100975037
            },
            "page": 0,
            "type": "chunkText"
        },
        "66a70ddf-280b-4fb6-9fab-611781e905f1": {
            "box": {
                "left": 0.1089007556438446,
                "top": 0.4528042674064636,
                "right": 0.8628273010253906,
                "bottom": 0.9112815260887146
            },
            "page": 0,
            "type": "chunkText"
        },
        "564a2df3-3a6f-47b8-aae4-a2e8d5335e25": {
            "box": {
                "left": 0.2166537046432495,
                "top": 0.9774618148803711,
                "right": 0.785216212272644,
                "bottom": 0.9998968839645386
            },
            "page": 0,
            "type": "chunkMarginalia"
        },
        "c96f98b0-87d6-4365-9f55-462f5d77ab54": {
            "box": {
                "left": 0.8406700491905212,
                "top": 0.9730968475341797,
                "right": 0.9733803868293762,
                "bottom": 0.9925980567932129
            },
            "page": 0,
            "type": "chunkMarginalia"
        }
    },
    "metadata": {
        "filename": "fyvw0217_35.png",
        "org_id": null,
        "page_count": 1,
        "duration_ms": 3698,
        "credit_usage": 3.0,
        "job_id": "pyujxi2l2d5rkxopmw7o59a59",
        "version": "dpt-2-20250919"
    }
}